Neonatal hypoglycemia and its management. (5 Marks)(KMCRI)** *Neonatal Hypoglycemia. (5 Marks) (GMC)
Reading File
Searching sources...
Finding Sources
Finding Sources
Good results found. Let me read the most relevant sections in parallel.
Reading File
Reading File
Reading File
Excellent. Now let me get more clinical details from Harriet Lane (Chapter 18 management section) and also search for causes/pathophysiology.
Finding Sources
Reading File
Now I have comprehensive information. Let me also search for clinical features and the Fig 18.2 management algorithm from Harriet Lane.
Finding Sources
Finding Sources
Finding Sources
Finding Sources
I have enough content from the textbooks. Let me now compile a comprehensive, exam-ready answer.
Neonatal Hypoglycemia
Definition
Neonatal hypoglycemia is defined as a serum glucose level insufficient to meet metabolic requirements. For practical clinical purposes:
- Point-of-care glucose (POCG) < 45-50 mg/dL within the first 48 hours of life
- < 70 mg/dL beyond 48 hours of life
- A common threshold used in term and late preterm infants: serum glucose < 40 mg/dL
Note: Bedside glucometers can be inaccurate by 10-15 mg/dL in the hypoglycemic range. A STAT plasma glucose must always be sent to confirm the diagnosis.
Incidence
- Affects approximately 15-25% of neonates born to women with diabetes
- Less common when tight maternal glycemic control is maintained during pregnancy and labor
Pathophysiology
After birth, the continuous transplacental glucose supply is abruptly cut. The neonate depends on:
- Glycogenolysis (breakdown of liver glycogen stores)
- Gluconeogenesis (from amino acids, lactate, glycerol)
- Lipolysis (free fatty acids as alternative fuel)
Failure of any of these mechanisms - or excessive glucose utilization (e.g., hyperinsulinemia) - leads to hypoglycemia.
Risk Factors / Causes
Classified into three broad categories:
1. Decreased Glucose Production / Substrate Deficiency
| Cause | Mechanism |
|---|---|
| Prematurity / SGA (IUGR) | Reduced hepatic glycogen stores, impaired gluconeogenesis |
| Perinatal asphyxia | Increased glucose consumption during anaerobic metabolism |
| Hypothermia | Depletes glycogen stores through thermogenesis |
| Polycythemia | Increased glucose utilization by excess RBCs |
| Sepsis / shock | Impaired gluconeogenesis, increased utilization |
2. Hyperinsulinemia (Excess Glucose Utilization)
| Cause | Notes |
|---|---|
| Infant of Diabetic Mother (IDM) | Most common cause in first 48 hours; transient due to chronic fetal hyperglycemia stimulating fetal beta cells |
| Beckwith-Wiedemann syndrome | Macroglossia, omphalocele, macrosomia + hypoglycemia |
| Congenital Hyperinsulinism | Dominant or recessive mutations in genes regulating beta-cell insulin secretion (most common cause beyond day 7) |
| Perinatal asphyxia / IUGR | Transient hyperinsulinemia |
| Maternal drug use | Terbutaline, beta-blockers, oral hypoglycemics |
3. Endocrine / Metabolic Disorders
- Hypopituitarism - Low GH and cortisol (look for midline defects, micropenis)
- Congenital adrenal hyperplasia
- Inborn errors of metabolism - fatty acid oxidation defects (e.g., MCAD deficiency), glycogen storage diseases
Clinical Features
Asymptomatic Hypoglycemia
- May be detected only on routine screening in at-risk neonates
Symptomatic Hypoglycemia
Neurogenic (adrenergic) symptoms:
- Jitteriness / tremors
- Tachycardia, diaphoresis, pallor
Neuroglycopenic symptoms:
- Hypotonia, lethargy
- Poor feeding, weak cry
- Apnea, cyanosis
- Seizures (may be subtle - eye deviation, lip smacking, tonic posturing)
- Coma (severe cases)
Untreated or undertreated neonatal hypoglycemia may lead to seizures, coma, and permanent brain damage, particularly when hypoglycemia persists beyond 2-24 hours (Creasy & Resnik's Maternal-Fetal Medicine).
Investigations / Workup
- Bedside glucometer - Screening tool only (may be inaccurate by 10-15 mg/dL)
- STAT plasma/serum glucose - Required for confirmed diagnosis
Additional workup if serum glucose consistently < 70 mg/dL after 48 hours:
- Serum insulin, C-peptide
- Growth hormone, cortisol
- Free fatty acids, beta-hydroxybutyrate
- Complete blood count with differential
- Blood, urine, CSF cultures (if sepsis suspected)
- Urinalysis
Glucagon stimulation test (interpret results):
- Rise in glucose ≥ 30 mg/dL + plasma insulin > 2 µU/mL + low free fatty acids (< 1.5 mmol/L) + low beta-hydroxybutyrate (< 2 mmol/L) + glucose requirement > 8 mg/kg/min → Hyperinsulinemia
- Low GH + low cortisol at time of hypoglycemia + midline defects + micropenis → Hypopituitarism
Management
Treatment Goals
| Population | Target glucose |
|---|---|
| High-risk neonates (no congenital disorder) < 48 hrs | Plasma glucose > 45-50 mg/dL |
| High-risk neonates (no congenital disorder) > 48 hrs | Plasma glucose > 60 mg/dL |
| Confirmed congenital hypoglycemia disorder | Plasma glucose > 70 mg/dL |
Step-by-Step Management
Step 1: Asymptomatic hypoglycemia in a stable neonate
- Encourage early and frequent breastfeeding (every 1-2 hours)
- Monitor glucose every 30-60 minutes until stable
- Dextrose gel (40% buccal dextrose, 0.5 mL/kg) can be used as an adjunct
Step 2: Symptomatic hypoglycemia OR glucose < 40 mg/dL
- IV Dextrose bolus: D10W at 2 mL/kg (= 200 mg/kg glucose) administered over 2-5 minutes
- Followed immediately by a continuous IV dextrose infusion
Step 3: IV Glucose Infusion Rate (GIR)
- Starting GIR: 6-8 mg/kg/min (using D10W at 80-100 mL/kg/day)
- Formula: GIR (mg/kg/min) = % Dextrose × rate (mL/hr) / (weight in kg × 6)
- Adjust GIR by no more than 2 mg/kg/min every 2 hours
- Monitor glucose every 30-60 minutes until stable, then 1-2 hourly
Step 4: Persistent / Refractory Hypoglycemia
| Drug | Dose | Mechanism |
|---|---|---|
| Glucagon | 0.02-0.03 mg/kg IV/IM/SC (max 1 mg) | Promotes glycogenolysis and gluconeogenesis |
| Diazoxide | 5-15 mg/kg/day PO in 3 divided doses | Keeps beta-cell K-ATP channels open → inhibits insulin secretion (1st-line for congenital hyperinsulinism) |
| Hydrocortisone | 5-10 mg/kg/day | For adrenal insufficiency / persistent hypoglycemia unresponsive to glucose |
| Octreotide | 2-10 mcg/kg/day SC | Somatostatin analog; inhibits insulin secretion (2nd-line for hyperinsulinism) |
Diazoxide carries a black box warning for pulmonary hypertension (rare but serious).
Step 5: Surgical management
- Near-total pancreatectomy for diffuse congenital hyperinsulinism refractory to medical therapy
Weaning IV Glucose
- Once glucose is stable for > 12-24 hours and oral feeds are established, wean GIR gradually (by 2 mg/kg/min every 2 hours)
- Never abrupt discontinuation - can cause rebound hypoglycemia
Prognosis / Complications
- Infants hypoglycemic for 2-24 hours or > 24 hours have significantly lower neurodevelopmental (adaptability) scores at age 2 years compared to controls
- Prolonged neonatal hypoglycemia increases risk of: cerebral palsy, epilepsy, learning difficulties, visual impairment
- IDM mothers who gained excess weight had infants with longer duration of hypoglycemia
Prevention
- Tight maternal glycemic control during pregnancy and labor (reduces incidence significantly)
- Early skin-to-skin contact and breastfeeding within first hour
- Glucose screening protocol for all at-risk neonates (IDM, prematurity, SGA, LGA, perinatal asphyxia)
Key Sources:
- The Harriet Lane Handbook, 23rd Edition (Johns Hopkins) - Ch. 10 & 18
- Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice
- Pediatric Endocrine Society Guidelines (J Pediatr. 2015;167(2):238-245)
This is a shared conversation. Sign in to Orris to start your own chat.